Oncimmune’s CEO, Martin Gouldstone speaks to Vox Market about the company’s new strategy progress.

In this interview, CEO Martin Gouldstone of Oncimmune – a global leader in immune biomarkers and immunodiagnostics, speaks to Paul Hill of Vox Markets and discusses his journey to date, Oncimmune’s new strategy progress, as well as his thoughts on the market at large and some of the recent key trends. View the interview below: